Drug and Therapeutics Bulletin 2008;46:33-36; doi:10.1136/dtb.2008.04.0010
Copyright © 2008 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
PubMed
Right arrow PubMed Citation

{blacktriangledown}Varenicline for smoking cessation

Relevant BNF section: BNF 4.10

{blacktriangledown}Varenicline (pronounced va-re-nik-leen) (Champix – Pfizer), a nicotinic receptor partial agonist, is the first medicine of this type licensed for smoking cessation in adults. Launched in the UK in December 2006, the drug accounted for 14% of all prescription items and 22% of total expenditure, for smoking cessation products dispensed in the community in 2007*.1–4 Marketing materials claim that it has a "unique dual action", a "significantly higher quit rate" than bupropion, and a "favourable safety and tolerability profile". Here we discuss the evidence for varenicline and consider its role in smoking cessation.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2008 BMJ Publishing Group Ltd.